Liposomal cyclosporine A for treating bronchiolitis obliterans syndrome after lung transplant

Liposomal cyclosporine A (L-CsA) is currently in clinical development for the treatment of bronchiolitis obliterans syndrome (BOS) following a single or double lung transplant. BOS is a form of rejection in which the immune system causes the airways inside the lungs to become inflamed, which blocks the flow of oxygen through the lungs. BOS typically occurs in the first year after a lung transplant but could occur up to a decade later. Symptoms of BOS include a dry cough, shortness of breath and wheezing. BOS is a debilitating and life-threatening disease, and there remains a need for effective treatments with better tolerability and method of administration.